NEW YORK, May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Supernus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April ...